MarcPeterBonacaMD

Cardiology • Aurora, CO

Non-Invasive Cardiology, Preventive Cardiology, Vascular Medicine

Instructor in Medicine, Brigham and Women's Hospital

Join to view full profile

Dr. Bonaca is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bonaca's full profile

Already have an account?

Office
13199 E Montview Blvd
Suite 200
Aurora, CO 80045

Summary

Dr. Marc Bonaca is a cardiologist in Aurora, CO and is affiliated with multiple hospitals in the area, including Brigham and Women's Hospital and University of Colorado Hospital. He received his medical degree from University of Connecticut School of Medicine and has been in practice 14 years. He specializes in adult cardiology and vascular medicine and is experienced in peripheral vascular disease.

Education & Training

Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Vascular Medicine, 2010 - 2011
Harvard School of Public HealthMPH, Public Health, 2008 - 2011
Brigham and Women's HospitalFellowship, Cardiovascular Disease, 2006 - 2009
Brigham and Women's HospitalResidency, Internal Medicine, 2003 - 2006
Uconn School Of MedicineClass of 2003

Certifications & Licensure

CO State Medical License 2019 - 2025
MA State Medical License 2005 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737) Start of enrollment: 2007 Sep 01
Completed
Phase 3
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin Start of enrollment: 2010 Oct 01
Completed
Phase 3
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events Start of enrollment: 2013 Apr 25
Completed
Phase 3
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities Start of enrollment: 2015 Aug 18
Completed
Phase 3
Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease Start of enrollment: 2017 Jan 23
Completed
Phase 2
A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction Start of enrollment: 2018 Jun 05
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

247 citations
Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology
Marc P. Bonaca, Benjamin A. Olenchock, Joe-Elie Salem, Stephen D. Wiviott, Stéphane Ederhy
Circulation. 2019-07-02
178 citations
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
Thomas A Zelniker, Marc P. Bonaca, Remo H.M. Furtado, Ofri Mosenzon, Julia F Kuder
Circulation. 2020-04-14
665 citations
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.
Joe-Elie Salem, Ali Manouchehri, Melissa Y.Y. Moey, Bénédicte Lebrun-Vignes, Lisa Bastarache
The Lancet. Oncology. 2018-12-01

Journal Articles

Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines
Nicholas A Marston, Marc P Bonaca, Petr Jarolim, Deepak L Bhatt, Stephen D Wiviott, Eugene Braunwald, Marc S Sabatine, JAMA Cardiology
ASCVD Risk and Statin Use in PAD
Marc Bonaca, MD, JACC: Cardiovascular Imaging
Rivaroxaban in Peripheral Artery Disease After Revascularization
Marc Bonaca, MD, The New England Journal of Medicine
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Stephen D Wiviott, Marc S Sabatine, Christian T Ruff, Marc P Bonaca, Deepak L Bhatt, Darren K McGuire, The New England Journal of Medicine
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Marc Bonaca, MD, The New England Journal of Medicine
Pathology of Arterial Disease in Limb Loss
Mark A Creager, Marc P Bonaca, ScienceDirect
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Erin A Bohula, Stephen D Wiviott, Benjamin M Scirica, Darren K McGuire, Marc S Sabatine, Marc P Bonaca, Christian T Ruff, Silvio E Inzucchi, The New England Journal of Medicine
Antithrombotic Therapy in Patients with Peripheral Artery Disease
Marc Bonaca, MD, JAMA
Join now to see all

Lectures

Novel Approaches in Diabetic Patients After PCI: Role of SGLT2 Inhibitors and Potent Antiplatelet Therapy (THEMIS)
CRF Transcatheter Cardiovascular Therapeutics - Annual Symposium 2019 - Miami, FL - 9/26/2019
The Role of Antiplatelet Agents in Patients With Diabetes and Coronary Disease
CRF Transcatheter Cardiovascular Therapeutics - Annual Symposium 2019 - Miami, FL - 9/26/2019
Highlights in Peripheral Artery Disease
2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE TIMI 58
2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
ARS Case 4 Pre
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
ARS Case 5 Post
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
ARS Case 2 Post
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
ARS Case 5 Pre
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
ARS Case 2 Pre
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
ARS Post Debate Both an Antiplatelet and an Anticoagulant or Just an Anticoagulant?
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
Antithrombotic Management: From Venous Thromboembolism to Vascular Protection
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
ARS Case 3 Post
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
ARS Case 3 Pre
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
ARS Case 1 Post
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
ARS Case 4 Post
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
ARS Case 1 Pre
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
Vasculo-Oncology 2019: An Emerging Field--Be a Part of It
2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019
Stop It Late: The Benefit for Secondary Prevention is Clear
2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019
Join now to see all

Authored Content

What Is Optimal Medical Therapy for CLTI? Can We Move the Needle with Drugs Alone?October 2020
Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol GuidelinesAugust 2020
ASCVD Risk and Statin Use in PADJuly 2020
Rivaroxaban in Peripheral Artery Disease After RevascularizationMarch 2020
Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients with Multivessel Coronary DiseaseJanuary 2018
Reply Cost-Effectiveness of Long-Term Ticagrelor in Patients with Prior Myocardial Infarction: Analysis by SubgroupsJanuary 2018
Join now to see all

Press Mentions

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTKNovember 5th, 2024
Updated Guidelines Tackle Management of Peripheral Arterial and Aortic DiseasesOctober 8th, 2024
Interactive Map Highlights PAD Amputation Risks; Experts Call for ActionSeptember 3rd, 2024
Join now to see all